文献速递胸部肿瘤

非小细胞肺癌中检查点抑制剂诱导的毒性效应与肿瘤及组织共享抗原的关联

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项前瞻性队列研究纳入73例接受抗PD-1治疗的非小细胞肺癌患者,发现34.2%出现自身免疫性皮肤毒性,且完全或部分缓解者皮肤毒性发生率高于进展或稳定者。研究鉴定出肿瘤与皮肤共享的9种T细胞抗原,这些抗原可在体外刺激CD8+和CD4+ T细胞,为检查点抑制剂相关自身免疫毒性机制及其与疗效的关联提供了线索。

要点

  • 73例接受抗PD-1治疗的非小细胞肺癌患者中,34.2%出现自身免疫性皮肤毒性。
  • 完全或部分缓解者皮肤毒性发生率为68.2%,高于进展或稳定者的19.6%。
  • 鉴定出肿瘤与皮肤共享的9种T细胞抗原,可在体外刺激CD8+和CD4+ T细胞。

核心结论

  • 这些发现突出了检查点抑制剂介导的自身免疫毒性的一种潜在机制,并描述了毒性效应与治疗缓解之间的关联。
  • 作者认为这种理解有助于控制不良反应、解析新的肿瘤抗原并进一步改善免疫治疗。

研究设计与样本

  • 前瞻性队列研究,2016年7月1日至2018年12月31日开展。
  • 纳入73例接受抗PD-1治疗(纳武利尤单抗或帕博利珠单抗)的非小细胞肺癌患者,来自瑞士4个中心(Kantonsspital St Gallen、Spital Grabs、Spital Wil和Spital Flawil)。
  • 在2年期间收集外周血单核细胞、肿瘤活检标本和自身免疫性皮肤毒性部位活检,患者随访1年。

主要发现

  • 73例患者平均(SD)年龄68.1(8.9)岁,44例(60%)为男性。
  • 25例(34.2%[95%CI,24.4%-45.7%])出现自身免疫性皮肤毒性。
  • 完全缓解或部分缓解者皮肤毒性发生率为68.2%(95%CI,47.3%-83.6%),高于进展或稳定者的19.6%(95%CI,11.0%-32.5%)(χ2=14.02,P<.001)。
  • 鉴定出肿瘤组织与皮肤共享的9种T细胞抗原,这些抗原可在体外刺激CD8+和CD4+ T细胞。
  • 在抗PD-1治疗有效的患者中,血液样本中发现的若干抗原特异性T细胞也存在于自身免疫性皮肤病变和肺部肿瘤中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immunotherapy with checkpoint inhibitors targeting the PD-1 (programmed cell death 1) axis has brought notable progress in patients with non-small cell lung cancer (NSCLC) and other cancers. However, autoimmune toxic effects are frequent and poorly understood, making it important to understand the pathophysiologic processes of autoimmune adverse effects induced by checkpoint inhibitor therapy. OBJECTIVE: To gain mechanistic insight into autoimmune skin toxic effects induced by anti-PD-1 treatment in patients with non-small cell lung cancer. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted from July 1, 2016, to December 31, 2018. Patients (n = 73) with non-small cell lung cancer who received anti-PD-1 therapy (nivolumab or pembrolizumab) were recruited from 4 different centers in Switzerland (Kantonsspital St Gallen, Spital Grabs, Spital Wil, and Spital Flawil). Peripheral blood mononuclear cells, tumor biopsy specimens and biopsies from sites of autoimmune skin toxic effects were collected over a 2-year period, with patient follow-up after 1 year. MAIN OUTCOMES AND MEASURES: Response to treatment, overall survival, progression-free survival, and development of autoimmune toxic effects (based on standard laboratory values and clinical examinations). RESULTS: Of the cohort of 73 patients with NSCLC (mean [SD] age, 68.1 [8.9] years; 44 [60%] men), 25 (34.2% [95% CI, 24.4%-45.7%]) developed autoimmune skin toxic effects, which were more frequent in patients with complete remission or partial remission (68.2% [95% CI, 47.3%-83.6%]) than those with progressive or stable disease (19.6% [95% CI, 11.0%-32.5%]) (χ2 = 14.02, P < .001). Nine T-cell antigens shared between tumor tissue and skin were identified. These antigens were able to stimulate CD8+ and CD4+ T cells in vitro. Several of the antigen-specific T cells found in blood samples were also present in autoimmune skin lesions and lung tumors of patients who responded to anti-PD-1 therapy. CONCLUSIONS AND RELEVANCE: These findings highlight a potential mechanism of checkpoint inhibitor-mediated autoimmune toxic effects and describe the association between toxic effects and response to therapy; such an understanding will help in controlling adverse effects, deciphering new cancer antigens, and further improving immunotherapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Berner F, Bomze D, Diem S, et al. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol. 2019. PMID: 31021392. doi:10.1001/jamaoncol.2019.0402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。